Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Bialystok – page 5

579 clinical trials in Bialystok, Poland across 9 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Bialystok at a glance
579
clinical trials
  • Research sites9
Type of trial
Recruitment status
Quick filters

579 trials in Bialystok

Open in trial search

A Phase 3 Randomized, Double-blind,Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-2)

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Efficacy, safety and dose‑response of once‑weekly subcutaneous UBT251 compared with semaglutide in adults with type 2 diabetes

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:BeOne Medicines I GmbH

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Obesity

Recruiting

Phase III randomized trial of elecoglipron to assess safety and weight loss in adults with obesity or overweight, with or without type 2 diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Bialystok

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on bladder cancer treatment using combination therapies, and innovative approaches for advanced breast cancer management. Research includes novel treatments for various solid tumors and gynecological malignancies.

  • Non-muscle invasive bladder cancer treatment
  • Advanced/metastatic breast cancer therapies
  • Gynecological tumor treatments

Investigations emphasize combination therapies and targeted treatment approaches.

02 Neurological & Mental Health

Clinical research targeting early Alzheimer's disease, exploring new treatments to slow disease progression and improve cognitive function.

  • Alzheimer's disease progression
  • Cognitive function assessment
  • Disease-modifying therapies

Focus on developing interventions for early-stage neurological conditions.

03 Inflammatory Conditions

Comprehensive studies on various inflammatory conditions including psoriatic arthritis, plaque psoriasis, and Crohn's disease. Research spans both biologic-naive and experienced patients.

  • Moderate to severe plaque psoriasis
  • Active psoriatic arthritis treatments
  • Chronic rhinosinusitis management

Evaluating novel therapeutic approaches for inflammatory disorders.

04 Metabolic & Cardiovascular Health

Studies addressing obesity, chronic kidney disease, and heart failure prevention. Research includes innovative treatments for weight management and cardiovascular risk reduction.

  • Obesity and weight management
  • Heart failure prevention
  • Chronic kidney disease treatments

Integration of multiple therapeutic approaches for complex metabolic conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.